SCHEDULE: State Street Discloses 6.3% Stake in Ultragenyx

State Street Corporation has reported beneficial ownership of 6,158,766 shares, representing 6.3% of the outstanding common stock of Ultragenyx Pharmaceutical Inc., as of June 30, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 6,158,766 shares of Ultragenyx Pharmaceutical Inc. common stock.
• This holding represents 6.3% of the class of securities.
• The filing is dated June 30, 2026, and State Street Corporation is identified as a holder of more than 5 percent of the class of securities.
• The shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine Schedule 13G filing indicating a significant but not controlling stake by an institutional investor.

Positives

• State Street Corporation, a major institutional investor, holds a significant stake in Ultragenyx Pharmaceutical Inc., which can be seen as a vote of confidence.
• The filing confirms a substantial institutional presence, potentially increasing liquidity and investor interest in the stock.

Negatives

• The filing does not contain any negative financial or operational information about Ultragenyx Pharmaceutical Inc. itself, as it is a disclosure by an investor.
• The nature of a 13G filing means it's a passive investment, not an active engagement or endorsement of management's strategy.

Risks

• The primary risk is that State Street Corporation, as a large institutional holder, could decide to sell a significant portion of its shares, potentially impacting the stock price.
• While not explicitly stated as a risk in this filing, any future changes in State Street's investment strategy or market conditions could lead to divestment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Ultragenyx Pharmaceutical Inc.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that institutional ownership, as disclosed in Schedule 13G filings, is a common indicator of investor interest in the biotechnology and pharmaceutical sectors. A significant stake by a large entity like State Street Corporation suggests a positive view on the company's long-term prospects within the industry.

Comparison to Industry Standards

• As a Schedule 13G filing, it reports passive ownership. Industry standards for institutional ownership in mid-cap biotechnology companies typically range from 50% to 80%. A 6.3% stake by a single institutional investor is substantial but within typical ranges for a significant holder.
• Competitors in the rare disease and gene therapy space, such as Sarepta Therapeutics or BioMarin Pharmaceutical, also see significant institutional ownership, often with multiple holders exceeding 5%.

Stakeholder Impact

• Shareholders: The presence of a large institutional holder like State Street Corporation can provide stability and potentially attract further investment. However, any significant selling by State Street could negatively impact share price.
• Creditors: No direct impact mentioned.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.

Next Steps

• State Street Corporation will continue to hold its shares in Ultragenyx Pharmaceutical Inc. in the ordinary course of business.
• Ultragenyx Pharmaceutical Inc. will continue its operations and business development as usual, subject to market conditions and its strategic plans.

Key Dates

Keywords

Ultragenyx Pharmaceutical, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Securities Exchange Act